TG Therapeutics- Relapsing forms of Multiple Sclerosis
Living with a relapsing form of multiple sclerosis means that long-term, consistent management is not optional – it is essential. At Lone Star Neurology in Texas, we are currently enrolling participants for a landmark Briumvi clinical trial sponsored by TG Therapeutics. This study focuses on Ublituximab MS therapy, specifically the FDA-approved medication BRIUMVI®, and is designed to evaluate its long-term effectiveness and safety profile over approximately 192 weeks.
For those seeking a relapsing MS treatment that offers a clear, structured path forward, this study represents a genuinely unique opportunity – one that provides access to specialist care while contributing directly to the future of neurological medicine. To be eligible, you must be a patient who has already been prescribed BRIUMVI by your neurologist but has not yet received your first infusion. If you have been searching for an MS clinical trial near me in the Texas area, our team is ready to guide you through every step of the process and determine whether this long-term program is the right fit for your MS journey. Call us today at 214-619-1910 to get started.
What Are Relapsing Forms of MS?
Multiple sclerosis is not a single, uniform condition. It presents differently in every patient. However, a large proportion of those diagnosed fall into what clinicians refer to as relapsing forms. This category primarily includes Relapsing-Remitting MS (RRMS) and active Secondary Progressive MS (SPMS). In both cases, patients experience defined periods of neurological deterioration, known as relapses, followed by intervals of partial or complete recovery called remission.
Living with relapsing multiple sclerosis often feels deeply unpredictable. One month may bring relative stability; the next may bring debilitating fatigue, significant numbness, or meaningful loss of mobility. At the biological level, the disease involves the immune system repeatedly attacking the myelin sheath – the protective coating surrounding your nerve fibers. Each inflammatory episode carries the potential for cumulative, irreversible nerve damage over time.
This is precisely why consistent, long-term treatment is so critical. With the right therapy and a dedicated clinical team, patients can meaningfully reduce the frequency of relapses and preserve their quality of life far longer than without intervention. Among the MS treatment options now available, anti-CD20 therapies like Ublituximab represent one of the most promising and clinically supported approaches to managing relapsing multiple sclerosis.
About the Briumvi (Ublituximab) Long-Term Study
This Briumvi clinical trial is classified as an open-label study – meaning that both the treating physicians and the participants know exactly which medication is being administered. There is no placebo component in this phase of the research. The study’s focus is entirely on tracking the real-world safety and effectiveness of BRIUMVI® (Ublituximab-xiiy) as patients use it consistently over approximately four years – 192 weeks in total.
Throughout the study, participants will attend regularly scheduled MS infusion therapy visits at our clinic. At each visit, our dedicated medical team will conduct routine safety assessments, monitor vital signs, and carefully evaluate how your MS symptoms are responding to treatment. Comprehensive MRI monitoring is also incorporated to track any changes in disease activity over time.
Participation in this multiple sclerosis research study is entirely voluntary. You may withdraw at any time, for any reason, without consequence. That said, the extended 192-week duration is specifically designed to give researchers the most complete and clinically meaningful picture of how Ublituximab MS therapy performs over the long term. Being part of this structured program means having a dedicated team of specialists focused on every aspect of your neurological health – a level of personalized oversight that goes far beyond what is available through routine outpatient care.
Who May Be Eligible?
The eligibility criteria for this relapsing MS treatment study are precise and carefully defined to ensure participant safety and the scientific integrity of the data. You may be a strong candidate for the BRIUMVI long-term study if you meet the following requirements:
- Age. You must be 18 years of age or older.
- Diagnosis. You must have a confirmed diagnosis of a relapsing form of multiple sclerosis.
- Health Status. You must not have any active, serious infections at the time of enrollment.
- Treatment History. You have never received BRIUMVI® (Ublituximab-xiy) before.
- Current Status. You must hold a current prescription for BRIUMVI from your neurologist, but must not yet have received your first 150 mg infusion.
These are the foundational eligibility parameters for this multiple sclerosis research study. Our clinical study team makes final enrollment decisions following a thorough, individualized screening process. Our priority is always to confirm that participation is the safest and most beneficial choice for your specific health circumstances.
What to Expect as a Study Participant
Beginning a research study can feel like a significant step into the unknown. At Lone Star Neurology, we are committed to making that transition as smooth, clear, and supported as possible.
Your journey starts with a screening visit during which we review your complete medical history and verify that you meet all enrollment criteria. Once cleared, you will receive your first MS infusion therapy session at our clinic under the direct supervision of our specialist team. Because this is a long-term study, you will return for regularly scheduled infusion visits as defined by the study protocol throughout the 192-week program.
Throughout those four years, you will receive far more than a routine treatment. You will be under the continuous oversight of board-certified neurologists who specialize exclusively in MS. They will monitor your neurological function at every visit, review MRI results for any meaningful changes, and ensure the medication is being well-tolerated. Among the MS treatment options available today, few provide this level of sustained, expert-led monitoring. Joining this study gives you a front-row seat to your own care – with a highly qualified team focused entirely on your safety and progress.
Benefits and Risks of Participation
Every meaningful medical decision requires an honest evaluation of both potential benefits and realistic risks.
Potential benefits of participation include:
- Long-term, structured access to Ublituximab MS therapy at no personal cost
- Significantly more frequent and detailed neurological monitoring than is typically available in a standard clinical setting
- A meaningful contribution to a multiple sclerosis research study that will help physic
Potential risks to be aware of:
- As with any high-efficacy biological therapy, there are potential Briumvi side effects to consider. The most commonly reported are infusion-related reactions – including itching, rash, or headache – that occur during or shortly after treatment.
- Because BRIUMVI modulates the immune system, there is a modestly increased risk of infections, most notably respiratory tract infections.
Our clinical team is fully trained to promptly identify, manage, and treat these reactions. Continuous monitoring throughout the study ensures that any Briumvi side effects are caught and addressed at the earliest possible stage. We will discuss all risks in detail during your initial consultation so you can make a fully informed and confident decision.
How to Apply - Contact Lone Star Neurology
If you are ready to explore this opportunity, the first step is simply reaching out. We are actively enrolling eligible patients and welcome every inquiry. You can apply by completing our online contact form – we will need a few essential details to begin the screening process:
- Full name and contact information
- Date of birth (to confirm you are 18 or older)
- Confirmation of your relapsing MS diagnosis
- Verification that you hold a current BRIUMVI prescription but have not yet started infusions
Once your information is submitted, a dedicated study coordinator will contact you promptly to walk you through the next steps, answer your questions, and schedule your initial screening appointment. If you prefer to speak with someone directly or have questions about finding a clinical trial near me in Texas, do not hesitate to call us.
Contact Information:
- Phone: 214-619-1910
- Location: Lone Star Neurology, Texas
- Study ID: ClinicalTrials.gov – NCT04130997
- Status: Currently Enrolling
Taking control of your MS journey begins with a single step. We are here to provide the expertise, the resources, and the comprehensive care you deserve. Reach out to Lone Star Neurology today and find out whether this important MS clinical trial near me is the right path forward for you.
